Result for
Tag: variants
March 3, 2021
Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization
[Pre-print, not peer-reviewed] Reduced neutralization titers against the P.1 SARS-CoV-2 variant were found in both convalescent plasma (6.5-fold) and plasma from individuals who received an mRNA vaccine (2.2-2.8-fold). The P.1 variant completely resisted neutralization by multiple neutralizing monoclonal antibodies. Using a VSV-based SARS-CoV-2 pseudovirus with all 10 mutations of the P.1 variant, the authors note…
Sequence Analysis of 20453 SARS-CoV-2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern
[Pre-print, not peer-reviewed] Genomic sequencing of 20,453 virus specimens in Houston, Texas identified the presence of all variants of interest or concern (n=23 of B.1.1.7, n=2 of B.1.351, n=4 of P.1, and n=143 of B.1.429 and n=19 of B.1.427). None of the affected patients were from a common household or reported recent international travel, suggesting…
Travel from the United Kingdom to the United States by a Symptomatic Patient Infected with the SARS-CoV-2 B.1.1.7 Variant — Texas, January 2021
On January 10, 2021, an individual infected with the SARS-CoV-2 B.1.1.7 variant was identified in Texas. No secondary cases with epidemiologic links to the patient have been identified to date. A case investigation revealed that the individual had traveled to the United Kingdom during November 13–December 30, 2020, and reported having been exposed to a…
First Identified Cases of SARS-CoV-2 Variant P.1 in the United States — Minnesota, January 2021
On January 25, 2021, the Minnesota Department of Health identified the first US cases of infection with the SARS-CoV-2 variant of concern P.1 (first identified in persons from Brazil) in two individuals, one of whom had a recent travel history to Brazil. Whole genome sequencing revealed identical sequences from both individuals, who lived in the…
Estimation of Secondary Household Attack Rates for Emergent SARS-CoV-2 Variants Detected by Genomic Surveillance at a Community-Based Testing Site in San Francisco
[Pre-print, not peer-reviewed] Some SARS-CoV-2 variants circulating in San Francisco with increasing prevalence may spread more efficiently to household contacts when compared to prior variants. Using SARS-CoV-2 genomic sequencing and epidemiological data collected from a walk-up rapid testing site in San Francisco, household contacts exposed to individuals infected with certain variants (including those with mutations…
March 2, 2021
Negligible Impact of SARS-CoV-2 Variants on CD4+ and CD8+ T Cell Reactivity in COVID-19 Exposed Donors and Vaccinees
[Pre-print, not peer-reviewed] Bioinformatic analysis suggests that memory T cells generated either by mild SARS-CoV-2 infection (n=11) or mRNA vaccines will not be affected by currently circulating variants. No significant differences were found in the capacity of CD4+ or CD8+ T cells isolated either from convalescent patients following mild disease or vaccinated individuals to recognize…
Reduced Antibody Cross-Reactivity Following Infection with B.1.1.7 than with Parental SARS-CoV-2 Strains
[Pre-print, not peer-reviewed] Convalescent sera from patients infected with the SARS-CoV-2 B.1.1.7 variant demonstrated reduced activity against reference strains from earlier in the pandemic. Neutralizing activity of sera isolated from patients that had confirmed infection by the SARS-CoV-2 B.1.1.7 variant (n=29) was reduced against a parental reference strain isolated from Wuhan by 3.4-fold. In contrast,…
March 1, 2021
Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] A study identifying the structural and functional determinants of serum with broad neutralization of SARS-CoV-2 determined that combinations of two antibodies with broadly neutralizing activity decrease the in vitro generation of escape mutants. The structural characteristics of four monoclonal receptor-binding domain-targeting antibodies isolated from three early-outbreak convalescent donors with broadly neutralizing polyclonal…
SARS-CoV-2 Spike D614G Change Enhances Replication and Transmission
The SARS-CoV-2 S-614G variant was found to enhance binding to recombinant human ACE2 receptors, increase replication in lung and nasal cell culture systems, increase replication in a humanized ACE2 mouse model, and increased transmissibility in hamster and ferret SARS-CoV-2 models. While this mutation resulted in small increases in binding and replication in vitro, it conferred…
February 25, 2021
Evidence of Escape of SARS-CoV-2 Variant B.1.351 from Natural and Vaccine Induced Sera
Neutralizing antibody titers were lower in assays against the SARS-CoV-2 B.1.351 variant compared to an early isolate from Wuhan across several sample sources. The geometric mean neutralizing titers were lower by 13.3-fold in convalescent plasma from patients infected during the first wave in the UK (n=34), by 3.1-fold in sera from patients infected with the…
Previous page Next page